28274609|t|Tongxinluo improves cognition by decreasing β-amyloid in spontaneous hypertensive rats
28274609|a|β-Amyloid (Aβ) accumulation in the brain is the major pathophysiology of Alzheimer disease (AD). Hypertension is a risk factor for AD by promoting Aβ deposition. Traditional Chinese medicinal compound tongxinluo (TXL) can improve blood circulation and endothelium -dependent vasodilation. This study investigates the effects of TXL on cognition and Aβ using spontaneously hypertensive rats (SHRs). TXL was intragastrically administered to SHRs at low-dose, mid- dose and high-dose for 15, 30 or 60 days. Cognition was evaluated with a Morris Water Maze (MWM). Aβ in the brain was detected by western blot, ELISA and Thioflavin-S staining. Western blot and RT-PCR were employed to exam the expression of receptor for advanced glycation end products (RAGE), low-density lipoprotein receptor-related protein-1 (LRP-1) and amyloid precursor protein (APP). After TXL treatment for 60 days, compared with the vehicle, the number of crossed platform and the time spent in the target quadrant increased in parallel with the increasing length of treatment in MWM. Moreover, the Aβ in the hippocampus significantly decreased compared to the vehicle group, both in western blot and ELISA. Additionally, TXL reduced RAGE expression in a dose - and time -depended manner, but LRP-1 expression had no difference between TXL groups and vehicle groups. Furthermore, the β-secretase expression was significantly decreased compared to the vehicle group, but APP expression had no difference. In conclusion, TXL improved cognition and decreased Aβ in SHRs in a dose - and time -dependent manner, the underlying mechanism may involved in inhibiting RAGE and β-secretase expression.
28274609	0	10	Tongxinluo	T123	C1742872
28274609	11	19	improves	T033	C0184511
28274609	20	29	cognition	T041	C0009240
28274609	33	43	decreasing	T033	C0442797
28274609	44	53	β-amyloid	T116	C3484390
28274609	57	86	spontaneous hypertensive rats	T015	C0034705
28274609	87	96	β-Amyloid	T116	C3484390
28274609	98	100	Aβ	T116	C3484390
28274609	102	114	accumulation	T033	C4055506
28274609	122	127	brain	T023	C0006104
28274609	141	156	pathophysiology	T169	C0031847
28274609	160	177	Alzheimer disease	T047	C0002395
28274609	179	181	AD	T047	C0002395
28274609	184	196	Hypertension	T047	C0020538
28274609	202	213	risk factor	T033	C0035648
28274609	218	220	AD	T047	C0002395
28274609	224	233	promoting	T052	C0033414
28274609	234	236	Aβ	T116	C3484390
28274609	237	247	deposition	T169	C0333562
28274609	249	278	Traditional Chinese medicinal	T091	C0025124
28274609	279	287	compound	T121	C0013229
28274609	288	298	tongxinluo	T123	C1742872
28274609	300	303	TXL	T123	C1742872
28274609	317	334	blood circulation	T039	C0005775
28274609	339	350	endothelium	T024	C0014257
28274609	362	374	vasodilation	T042	C0042401
28274609	381	386	study	T062	C2603343
28274609	387	399	investigates	T169	C1292732
28274609	404	414	effects of	T080	C1704420
28274609	415	418	TXL	T123	C1742872
28274609	422	431	cognition	T041	C0009240
28274609	436	438	Aβ	T116	C3484390
28274609	445	476	spontaneously hypertensive rats	T015	C0034705
28274609	478	482	SHRs	T015	C0034705
28274609	485	488	TXL	T123	C1742872
28274609	510	522	administered	T169	C1521801
28274609	526	530	SHRs	T015	C0034705
28274609	534	542	low-dose	T081	C0445550
28274609	549	553	dose	T081	C0178602
28274609	558	567	high-dose	T081	C0444956
28274609	585	589	days	T079	C0439228
28274609	591	600	Cognition	T041	C0009240
28274609	605	614	evaluated	T058	C0220825
28274609	622	639	Morris Water Maze	T059	C0022885
28274609	641	644	MWM	T059	C0022885
28274609	647	649	Aβ	T116	C3484390
28274609	657	662	brain	T023	C0006104
28274609	667	675	detected	T033	C0442726
28274609	679	691	western blot	T059	C0949466
28274609	693	698	ELISA	T059	C0014441
28274609	703	715	Thioflavin-S	T109,T130	C0952039
28274609	716	724	staining	T059	C0487602
28274609	726	738	Western blot	T059	C0949466
28274609	743	749	RT-PCR	T063	C0599161
28274609	776	786	expression	T045	C0597360
28274609	790	834	receptor for advanced glycation end products	T116,T192	C0101725
28274609	836	840	RAGE	T116,T192	C0101725
28274609	843	893	low-density lipoprotein receptor-related protein-1	T116,T192	C0051300
28274609	895	900	LRP-1	T116,T192	C0051300
28274609	906	931	amyloid precursor protein	T116	C0085151
28274609	933	936	APP	T116	C0085151
28274609	945	948	TXL	T123	C1742872
28274609	949	958	treatment	T169	C1522326
28274609	966	970	days	T079	C0439228
28274609	1103	1120	increasing length	T033	C0425939
28274609	1124	1133	treatment	T169	C1522326
28274609	1137	1140	MWM	T059	C0022885
28274609	1156	1158	Aβ	T116	C3484390
28274609	1166	1177	hippocampus	T023	C0019564
28274609	1192	1201	decreased	T081	C0205216
28274609	1241	1253	western blot	T059	C0949466
28274609	1258	1263	ELISA	T059	C0014441
28274609	1279	1282	TXL	T123	C1742872
28274609	1291	1295	RAGE	T116,T192	C0101725
28274609	1296	1306	expression	T045	C1171362
28274609	1312	1316	dose	T081	C0178602
28274609	1323	1327	time	T079	C0040223
28274609	1350	1355	LRP-1	T116,T192	C0051300
28274609	1356	1366	expression	T045	C1171362
28274609	1371	1384	no difference	T033	C3842396
28274609	1393	1396	TXL	T123	C1742872
28274609	1441	1452	β-secretase	T116,T126	C1454853
28274609	1453	1463	expression	T045	C1171362
28274609	1482	1491	decreased	T081	C0205216
28274609	1527	1530	APP	T116	C0085151
28274609	1531	1541	expression	T045	C1171362
28274609	1546	1559	no difference	T033	C3842396
28274609	1576	1579	TXL	T123	C1742872
28274609	1589	1598	cognition	T041	C0009240
28274609	1603	1612	decreased	T081	C0205216
28274609	1613	1615	Aβ	T116	C3484390
28274609	1619	1623	SHRs	T015	C0034705
28274609	1629	1633	dose	T081	C0178602
28274609	1640	1644	time	T079	C0040223
28274609	1679	1688	mechanism	T169	C0441712
28274609	1705	1715	inhibiting	T052	C3463820
28274609	1716	1720	RAGE	T116,T192	C0101725
28274609	1725	1736	β-secretase	T116,T126	C1454853
28274609	1737	1747	expression	T045	C1171362